ILLUMINA, INC. (ILMN): M&A transaction — Illumina completes $350M acquisition of SomaLogic from Standard BioTools

ILLUMINA, INC.

Purchase price $350M in cash plus up to $75M in performance milestones and royalties.
SomaLogic's proteomics tech (SomaScan, SomaSignal) expands Illumina's multiomics portfolio.
Acquisition funded with cash on hand; financial impact discussed on Feb 5, 2026 earnings call.
Builds on co-development partnership established in 2021 for NGS-based proteomics.

item 2.01 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

M&A Transactions SEC 8-K Item 2.01/5.01 confidence 0.9

ILLUMINA, INC. completed an acquisition involving Standard BioTools Inc. for $350,000,000 in cash (closed 2026-01-30).

Action: acquisition
Counterparty: Standard BioTools Inc.
Consideration: $350,000,000 in cash
Closing: 2026-01-30

Exact text from the filing

BioTools’s mass cytometry and microfluidics businesses (the “Business”). On January 30, 2026, the Company completed the Transaction. The Company paid a purchase price of $350,000,000 in cash, subject to customary adjustments. The Purchase Agreement further provides for, in connection with the revenues generated from certain products and services, (i) royalty

View on SEC.gov

8 m&a transactions filed in the last 30 days. Browse all m&a transactions →

ILLUMINA, INC. filing history →

Source: SEC EDGAR

accession 0001110803-26-000014

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.